ASLAN Pharmaceuticals Limited Stock Taipei Exchange
Equities
6497
KYG054241099
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 308M 9.5M |
---|---|---|---|---|---|
Net income 2024 * | -1.72B -52.98M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.13
x | P/E ratio 2025 * |
-0.18
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Managers | Title | Age | Since |
---|---|---|---|
Carl Firth
FOU | Founder | 51 | 09-12-31 |
Kiran Asarpota
DFI | Director of Finance/CFO | 45 | 10-10-31 |
Chief Tech/Sci/R&D Officer | - | 22-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 18-10-29 |
Andrew Howden
CHM | Chairman | 64 | 16-03-31 |
Carl Firth
FOU | Founder | 51 | 09-12-31 |
1st Jan change | Capi. | |
---|---|---|
+3.82% | 108B | |
+11.09% | 104B | |
+1.28% | 22.33B | |
-12.88% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.35% | 17.64B | |
+3.40% | 14.05B | |
+37.16% | 12.51B |